Nisha Abdul Rehuman, Bijo Mathew*, Rakesh Kumar Jat, Orazio Nicolotti and Hoon Kim Pages 1 - 18 ( 18 )
Background: Monoamine oxidases (MAOs) play a crucial role during the development of various neurodegenerative disorders. There are two MAO isozymes, MAO-A and MAO-B. MAO-A is a flavoenzyme, which binds to the outer mitochondrial membrane and catalyzes the oxidative transformations of neurotransmitters like serotonin, norepinephrine, and dopamine.
Materials and Methods: Focus on synthetic studies has culminated in the preparation of many MAO-A inhibitors, and advancements in combinatorial and parallel synthesis have accelerated the developments of synthetic schemes. Here, we provide an overview of the synthetic protocols employed to prepare different classes of MAO-A inhibitors. We classify these inhibitors according to their molecular scaffolds and the synthetic methods used.
Results: Various synthetic and natural derivatives from different class of MAO-A inhibitors were reported.
Conclusion: The review provides a valuable tool for the development of new class of various selective MAO-A inhibitors for the treatment of depression and other anxiety disorders.
MAO-A, MAO-B, Inhibitors, Neurotransmitters, Molecular scaffolds, neurodegenerative disorders.
Department of Pharmaceutical Chemistry, Dr. Joseph Mar Thoma Institute of Pharmaceutical Sciences & Research, Kerala 690503, Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, Kerala, Department of Pharmaceutical Chemistry, JJTU university, Jhunjhunu, Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari “Aldo Moro”, via E. Orabona, 4, I-70125 Bari, Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922